title: [Haematological parameters evolution during the antiretroviral therapy of HIV infected patients in Burkina-Faso].
abstract: Haematological anomalies are frequent during HIV infection, and can be the fact of virus and or bone marrow toxicity of antiretroviral drugs. In order to analyze the evolution of the haematological parameters during HAART this work was carried out in the internal medicine department of the national teaching hospital Yalgado-Ouédraogo in Ouagadougou. So 107 patients receiving for the first time HAART and followed regularly were retained. The immunological efficacy at the end of the first six months was 60, 75% with an average gain of 119 CD4/mm3. The haematological changes at the end of these first six months showed: --an anaemia in 51.4% of the cases at month 6 versus 80.3% at baseline (p=0.0001). The average rate of haemoglobin was 11.8 versus 11.2 g/dl at baseline in the AZT containing HAART regimen (p=0.014) and 12.2 versus 10.7 g/dl at baseline in the group without AZT (p=0.00006). --a neutropenia in 35.5% of the cases at month 6 versus 31.7% at baseline (p=0.6). The average rate of neutrophil was 1908/mm3 versus 2267.1/mm3 at baseline in the AZT containing HAART regimen and 2150.7/mm3 versus 2001.9/mm3 at baseline in the group without AZT These results show that the therapeutic efficacy measured on the immunological answer is accompanied by a reduction of haematological anomalies. They also suggest the necessity to evaluate the cotrimoxazole impact before deciding the interruption of AZT.
authors.affiliation: Service de médecine interne du CHU Yalgado-Ouédraogo, 01 BP 2251 Ouagadougou, Burkina Faso. newcool18@hotmail.com
authors.forename: E W C
authors.initials: EW
authors.lastname: Nacoulma
authors.forename: Y
authors.initials: Y
authors.lastname: Some
authors.forename: H
authors.initials: H
authors.lastname: Tieno
authors.forename: I
authors.initials: I
authors.lastname: Diallo
authors.forename: A
authors.initials: A
authors.lastname: Zoungrana
authors.forename: R
authors.initials: R
authors.lastname: Bougnounou
authors.forename: C
authors.initials: C
authors.lastname: Ouédraogo
authors.forename: J
authors.initials: J
authors.lastname: Drabo
authors.forename: J B
authors.initials: JB
authors.lastname: Guiard-Schmid
mesh_terms: D000293:Adolescent; D000328:Adult; D000740:Anemia / Q000139:chemically induced; D000890:Anti-Infective Agents / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D002050:Burkina Faso; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000188:drug therapy*; D006402:Hematologic Diseases / Q000139:chemically induced*; D006454:Hemoglobins / Q000187:drug effects; D006801:Humans; D008231:Lymphopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D012189:Retrospective Studies; D013921:Thrombocytopenia / Q000139:chemically induced; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use; D015215:Zidovudine / Q000009:adverse effects
chemical_list: D000890:Anti-Infective Agents; D006454:Hemoglobins; D015215:Zidovudine; D015662:Trimethoprim, Sulfamethoxazole Drug Combination